TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05350085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: ① initial dose: use a micro injection pump to pump remimazolam at the rate of 50mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation ; ② Maintenance dose: maintain the pump speed at 5 \~ 10mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: ① initial dose: use a micro injection pump to pump remazolam at the rate of 30mg/h, and observe for 4 \~ 8 minutes until Ramsay Sedation grade III，then start dental operation; ② Maintenance dose: maintain the pump speed at 3 \~ 6mg/h，adjust the pump dose to maintain the patient at Ramsay Sedation grade III. ③ Additional dose: During the operation, if the patient has body movement reaction or cannot cooperate with the dentist, local anesthetics shall be given as remedy. ④ After the operation, stop the microinjection pump.
Study: NCT06619990

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: XmAb942
Description: Antibody

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: XmAb942
Description: Antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06673173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant
Description: A long cone paralleling approach with a specially made film holder will be used to assess each patient's vertical marginal bone loss to ensure standardized radiography analysis and avoid any magnification errors. The linear distance between the proximal crestal bone level and the implant shoulder will be measured at the mesial and distal aspects of the implant measured in millimeters (mm). Measurements will performed using image measurement software patient satisfaction comparison between 2 groups
Study: NCT04491383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocovid Suprabio (HOV-12020)
Description: Dietary supplement: Tocotrienol (HOV-12020) Palm oil-derived vitamin E, tocotrienol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary supplement: Placebo. Placebo.
Study: NCT04484441

Intervention type: OTHER
Intervention: Blood and placenta specimen collection.
Description: Collection of maternal and paternal blood. Collection of infant cord blood and placenta.

Intervention type: OTHER
Intervention: Blood and placenta specimen collection.
Description: Collection of maternal and paternal blood. Collection of infant cord blood and placenta.
Study: NCT05570539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BLU-5937 IR
Description: Each subject will receive two single and multiple administrations of Immediate Release reference formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-5937 ER
Description: Each subject will receive single and multiple oral administrations of Extended Release formulation
Study: NCT06069037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sequential adult left lateral lobe liver transplantation (SALT)
Description: SALT for patients who meet the enrollment conditions and successfully match the donor liver: Hemihepatectomy combined with left lateral lobe liver transplantation was performed first, and residual liver resection was performed after the graft grew to a sufficient functional liver volume.
Study: NCT04114890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir Disoproxil Fumarate 300 mg once daily and will continue until one month after delivery
Study: NCT04310345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal-Assisted Interactions
Description: Child and caregivers will spend approximately 10-5 minutes with a registered canine and its owner during potentially anxiety-producing visits to the clinic or hospital.
Study: NCT05365698

Intervention type: BEHAVIORAL
Intervention: Community Health and Nutrition Program
Description: The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods.

Intervention type: BEHAVIORAL
Intervention: Community Health and Nutrition Program
Description: The Community Health and Nutrition supported by the United States Agency for International Development (USAID) will be implemented by an international NGO, FHI 360. The goal of the Community Health and Nutrition (CHN) program is to improve the nutritional status of pregnant and lactating women (PLW) and children under the age of two years in the target areas of the Hashemite Kingdom of Jordan. The program will fulfill this goal by implementing activities to support improvements in IYCF practices, increase adoption of optimal family planning practices and maternal, infant and young child nutrition (MIYCN) practices, and by improving health care provider support for proper IYCF practices and use of modern contraceptive methods.
Study: NCT04738864

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: extracranial and intracranial ultrasound assessment

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: extracranial and intracranial ultrasound assessment
Study: NCT06245928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized Respiratory Exercise Device
Description: The Individualized Respiratory Exercise device will include both inspiratory muscle training, expiratory muscle training, and intensive spirometer features.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold® IMT + Threshold™ PEP
Description: The Threshold® IMT device allows inspiratory muscle training and the Threshold™ PEP device allows expiratory muscle training.
Study: NCT04857138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7300490
Description: Participants will receive RO7300490, as described in the Arm Descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7300490
Description: Participants will receive RO7300490, as described in the Arm Descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7300490
Description: Participants will receive RO7300490, as described in the Arm Descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive Atezolizumab, as described in the Arm Descriptions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive Atezolizumab, as described in the Arm Descriptions.
Study: NCT05441592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: No additional irrigation
Description: There will be no additional irrigation after the standard surgical procedure.
Study: NCT05110001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Ophthalmic
Description: Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Ophthalmic
Description: Topical moxifloxacin 0.5% is a fluoroquinolone antibiotic that is used to treat bacterial infections. This is a standard therapy for bacterial keratitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Topical chlorhexidine gluconate 0.02% is an antiseptic agent, with both antibacterial and antifungal properties. This is a standard therapy for Acanthamoeba keratitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natamycin
Description: Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.
Study: NCT04450914

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CV Prevention Choice Tool
Description: The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CV Prevention Choice Tool
Description: The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CV Prevention Choice Tool
Description: The CV Prevention Choice SDM tool is a shared decision making intervention. It is embedded in the electronic health record and uses EHR data to estimate and display cardiovascular risk for individual patients and then foster conversations between clinicians and patients about available options for preventive care based on individual risk and preferences.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation Facilitation Strategies
Description: During the active implementation stage, health systems will deploy tailored implementation facilitation and other tailored implementation strategies aimed at increasing adoption and use of shared decision making using CV Prevention Choice.
Study: NCT06633302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated multi-day heatwave exposure
Description: Older adults exposed to a multi-day simulated heat wave exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated multi-day heatwave exposure
Description: Older adults exposed to a multi-day simulated heat wave exposure
Study: NCT05730439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT06063460

Intervention type: OTHER
Intervention: 1. month periodontal evaluation and repeat questionnaire
Description: Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.

Intervention type: OTHER
Intervention: 1. month periodontal evaluation and repeat questionnaire
Description: Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.

Intervention type: OTHER
Intervention: 1. month periodontal evaluation and repeat questionnaire
Description: Periodontal examination will be performed in the 1st month, filling the questionnaire about halitosis, smell and taste perception.

Intervention type: OTHER
Intervention: 3. month periodontal evaluation and repeat questionnaire
Description: Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.

Intervention type: OTHER
Intervention: 3. month periodontal evaluation and repeat questionnaire
Description: Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.

Intervention type: OTHER
Intervention: 3. month periodontal evaluation and repeat questionnaire
Description: Periodontal examination will be performed in the 3rd month, filling the questionnaire about halitosis, smell and taste perception.
Study: NCT05597228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Stress Management and Health Education
Description: Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
Study: NCT05404789

Intervention type: OTHER
Group type: OTHER
Intervention: Centrifugation
Description: Subjects will participate in up to seven different centrifuge profiles over a single day of training (approximately 8 hours). Exposures are design to simulate a spaceflight profile using acceleration anticipated for commercial spaceflights.

Intervention type: OTHER
Group type: OTHER
Intervention: Centrifugation
Description: Subjects will participate in up to seven different centrifuge profiles over a single day of training (approximately 8 hours). Exposures are design to simulate a spaceflight profile using acceleration anticipated for commercial spaceflights.

Intervention type: OTHER
Group type: OTHER
Intervention: Centrifugation
Description: Subjects will participate in up to seven different centrifuge profiles over a single day of training (approximately 8 hours). Exposures are design to simulate a spaceflight profile using acceleration anticipated for commercial spaceflights.
Study: NCT05730439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive ZYN brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive ZYN brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive ZYN brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive ZYN brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive ZYN brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive ZYN brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive Rogue brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive Rogue brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive Rogue brand NP
Study: NCT06261294

Intervention type: DIAGNOSTIC_TEST
Intervention: OncoSweep Lung Spotligh
Description: This study is to develop and validate the performance of OncoSweep Lung Spotlight for detecting circulating miRNA expression, ctDNA methylation status, platelet RNA, and tumor marker expressions by utilizing real-time polymerase chain reaction (qPCR). The method is to collect venous blood from subjects during their routine visit to the healthcare facilities.
Study: NCT05730439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive Rogue brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive Rogue brand NP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Oral Pouch
Description: Receive Rogue brand NP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05918302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-edotreotide
Description: 6 cycles of 7.5 ± 0.7 Giga becquerel (GBq) 177Lu-edotreotide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 10 mg orally once daily (QD)
Study: NCT05110001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natamycin
Description: Natamycin 5% is an antifungal agent used to treat fungi that cause keratitis. This is a standard therapy for fungal keratitis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rose Bengal
Description: Study participants receive RB-PDT within 48 hours of randomization. All participants will receive a 30-minute loading dose of topical Rose Bengal (0.1% RB in 0.9% sodium chloride) which will be applied in 5-minute intervals to the de-epithelialized cornea. This will be followed by irradiation with a 6mW/cm2 custom-made green LED source for 15 minutes (5.4J/cm2). Repeat cornea culture will be collected within 24 hours after the procedure.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants receive sham RB-PDT within 48 hours of randomization. Participants will receive a 30-minute loading dose of topical balanced salt solution which will be applied in 5-minute intervals to the de-epithelialized cornea. A pen light covered with a green filter will be used for 15 minutes. Repeat cornea culture will be collected 30 minutes after the sham procedure.
Study: NCT05730439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smokeless Tobacco
Description: Receive usual SLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smokeless Tobacco
Description: Receive usual SLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smokeless Tobacco
Description: Receive usual SLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smokeless Tobacco
Description: Receive usual SLT
Study: NCT05523440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib oral capsule.
Study: NCT05116189

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study: NCT05730439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smokeless Tobacco
Description: Receive usual SLT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smokeless Tobacco
Description: Receive usual SLT
Study: NCT06547112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motixafortide
Description: Dose = 1.25 mg/kg via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motixafortide
Description: Dose = 1.25 mg/kg via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Dose = \~10 µg/kg (and maximum of 15 µg/kg) via subcutaneous injection
Study: NCT05367960

Intervention type: DRUG
Group type: OTHER
Intervention: Zatolmilast/ BPN14770
Description: 25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)
Study: NCT06530849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC012F Injection
Description: GC012F Injection is an autologous chimeric antigen receptor T cell therapy targeting both BCMA and CD19
Study: NCT04908137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-octyl cyanoacrylate
Description: Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D \& C Violet No. 2. It is provided as a single use applicator in a blister package
Study: NCT05116189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion
Study: NCT05494359

Intervention type: DIAGNOSTIC_TEST
Intervention: The nitrogen isotope
Description: The nitrogen isotope of various mass in oral gas were detected.

Intervention type: DIAGNOSTIC_TEST
Intervention: The nitrogen isotope
Description: The nitrogen isotope of various mass in oral gas were detected.

Intervention type: DIAGNOSTIC_TEST
Intervention: The nitrogen isotope
Description: The nitrogen isotope of various mass in oral gas were detected.
Study: NCT05371028

Intervention type: OTHER
Intervention: Non-interventional Study
Description: This is non-interventional study.
Study: NCT05521399

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Sequencing
Description: MRI test-retest (select healthy volunteers) for development of MRI sequence.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Testing (pediatric)
Description: Comprehensive cardiac MRI measures will be evaluated for the identification of complications after heart transplantation (ACR, CAV) in children.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI Testing
Description: Cardiac MRI to improve HTx monitoring for ACR and CAV as well as outcome prediction